Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma

Pediatric Blood and Cancer

Volumn 62, Issue 10, 2015, Pages 1739-1746

  Anderson, Clarke P ^a   Matthay, Katherine K ^b   Perentesis, John P ^c   Neglia, Joseph P ^d   Bailey, Howard H ^e   Villablanca, Judith G ^f   Groshen, Susan ^g   Hasenauer, Beth ^f   Maris, John M ^h   Seeger, Robert C ^f   Reynolds, C Patrick ⁱ  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Glutathione; Melphalan; Neuroblastoma; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; AMINOTRANSFERASE; BILIRUBIN; BUTHIONINE SULFOXIMINE; CEPHALOSPORIN; CREATININE; GLUTATHIONE; GRANULOCYTE COLONY STIMULATING FACTOR; ISOTRETINOIN; MELPHALAN; ANTINEOPLASTIC AGENT;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; AUTOPSY; BLOOD TOXICITY; BONE MARROW; BONE MARROW TRANSPLANTATION; BRAIN EDEMA; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CARDIOTOXICITY; CATHETER INFECTION; CELLULITIS; CENTRAL VENOUS CATHETER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION AT STEADY-STATE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; GLUCOSURIA; HERPETIC STOMATITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTRANSAMINASEMIA; IMMUNOCYTOCHEMISTRY; INDUCTION CHEMOTHERAPY; LEUKEMIA; LIVER TOXICITY; LOADING DRUG DOSE; LUNG TOXICITY; MAINTENANCE THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROBLASTOMA; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEINURIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; WHOLE BODY RADIATION; CHILD; DRUG EFFECTS; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEOPLASM RECURRENCE, LOCAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUTHIONINE SULFOXIMINE; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLUTATHIONE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MELPHALAN; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; PILOT PROJECTS;

EID: 84939567183     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25594     Document Type: Article

References (37)

1. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A 3973): A randomised phase 3 trial. Lancet Oncol 2013; 14:999-1008.
2. Matthay K, Villablanca JG, Seeger RC, Stram DO, Harris R, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing R, Reynolds CP. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341:1165-1173.
3. Seeger RC, Reynolds CP. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am 1991; 38:393-424.
4. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-1334.
5. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58:5396-5405.
6. Keshelava N, Zuo JJ, Chen P, Waidyaratne NS, Luna MC, Gomer CJ, Triche TJ, Reynolds CP. Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. Cancer Res 2001; 61:5103-5105.
7. Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NK, Boos J, Kohler G, Leuschner I, Pearson AD, Lunec J, Tweddle DA. High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin Cancer Res 2010; 16:1108-1118.
8. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 2001; 61:8-13.
9. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983; 52:711-760.
10. Tew KD, Houghton PJ, Houghton JA. Preclinical and clinical modulation of anticancer drugs. In: Preclinical and clinical modulation of anticancer drugs. Boca Raton: CRC Press; 1993. p. 13-17.
11. Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984; 44:5427-5431.
12. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985; 34:2583-2586.
13. Siemann DW, Beyers KL. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. Br J Cancer 1993; 68:1071-1079.
14. Tagde A, Singh H, Kang MH, Reynolds CP. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Blood Cancer J 2014; 4:e229.
15. Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds CP. Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res 1999; 246:183-192.
16. Yang B, Keshelava N, Anderson CP, Reynolds CP. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine. Cancer Res 2003; 63:1520-1526.
17. Anderson CP, Keshelava N, Satake N, Meek WH, Reynolds CP. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. Med Ped Oncol 2000; 35:659-662.
18. Lee FY, Allalunis Turner MJ, Siemann DW. Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine. Br J Cancer 1987; 56:33-38.
19. Terradez P, Asensi M, Lasso de la Vega MC, Puertes IR, Vina J, Estrela JM. Depletion of tumour glutathione in vivo by buthionine sulphoximine: Modulation by the rate of cellular proliferation and inhibition of cancer growth. Biochem J 1993; 292:477-483.
20. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. Phase I clinical trial of intravenous l-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione. J Clin Oncol 1994; 12:194-205.
21. Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G. Phase I study of continuous-infusion L-S, R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997; 89:1789-1796.
22. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14:249-256.
23. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 2000; 18:4067-4076.
24. Vandeputte C, Guizon I, Genestie-Denis I, Vannier B, Lorenzon G. A microtiter plate assay for total glutathione and glutathione disulfide contents in cultured/isolated cells: Performance study of a new miniaturized protocol. Cell Bio Toxicology 1994; 10:415-421.
25. Smithers J. A precolumn derivatization high-performance liquid chromatographic (HPLC) procedure for the quantitation of difluoromethylornithine in plasma. Pharm Res 1988; 5:684-686.
26. Adair CG, Burns DT, Crockard AD, Desai ZR, Harriott M. Modified extraction and chromatography for the measurement of plasma melphalan by ion-pair high-performance liquid chromatography. J Chromatogr 1984; 336:429-433.
27. Chang SY, Alberts DS, Melnick LR, Walson PD, Salmon SE. High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci 1978; 67:679-682.
28. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De BB, Evans AE, Favrot M, Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-1477.
29. Anderson CP, Seeger RC, Statake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediatr Hematol Oncol 2001; 23:500-505.
30. Anderson CP, Reynolds CP. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant 2002; 30:135-140.
31. Nicholls DG. Mitochondrial function and dysfunction in the cell: Its relevance to aging and aging-related disease. Int J Biochem Cell Biol 2002; 34:1372-1381.
32. Seyfried J, Soldner F, Schulz JB, Klockgether T, Kovar KA, Wullner U. Differential effects of l-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells. Neurosci Lett 1999; 264:1-4.
33. Andersen JK, Mo JQ, Hom DG, Lee FY, Harnish P, Hamill RW, McNeill TH. Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons. J Neurochem 1996; 67:2164-2171.
34. Skapek SX, VanDellen AF, McMahon DP, Postels DG, Griffith OW, Bigner DD, Friedman HS. Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. Cancer Chemother Pharmacol 1991; 28:15-21.
35. Berndt WO. The role of transport in chemical nephrotoxicity. Toxicol Pathol 1998; 26:52-57.
36. Tune BM, Hsu CY, Fravert D. Cephalosporin and carbacephem nephrotoxicity. Roles of tubular cell uptake and acylating potential. Biochem Pharmacol 1996; 51:557-561.
37. Manley HJ, Bailie GR, Eisele G. Bilateral renal cortical necrosis associated with cefuroxime axetil. Clin Nephrol 1998; 49:268-270.